Cost-eff ectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the iorra observational cohort study

Modern Rheumatology

Volumn 25, Issue 4, 2015, Pages 503-513

  Tanaka, Eiichi ^a   Inoue, Eisuke ^a   Hoshi, Daisuke ^a   Shimizu, Yoko ^a   Kobayashi, Akiko ^a   Sugimoto, Naoki ^a   Shidara, Kumi ^a   Sato, Eri ^a   Seto, Yohei ^a   Nakajima, Ayako ^a   Momohara, Shigeki ^a   Taniguchi, Atsuo ^a   Yamanaka, Hisashi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Cost effectiveness; Quality adjusted life years; Rheumatoid arthritis; The Japanese version of the Health Assessment Questionnaire; Tocilizumab

Indexed keywords

METHOTREXATE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DAS28; DISEASE COURSE; DRUG COST; ECONOMIC EVALUATION; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LIFE EXPECTANCY; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; IMMUNOLOGY; JAPAN; MALE; MIDDLE AGED; MULTICENTER STUDY; QUALITY OF LIFE; TREATMENT OUTCOME; TRENDS;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; JAPAN; MALE; METHOTREXATE; MIDDLE AGED; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, INTERLEUKIN-6; TREATMENT OUTCOME;

EID: 84935026789     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2014.1001475     Document Type: Article

References (59)

1. Filipovic I, Walker D, Forster F, Curry AS. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology. 2011;50(6):1083–90.
2. Tanaka E, Inoue E, Mannalithara A, Bennett M, Kamitsuji S, Taniguchi A, et al. Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study. Mod Rheumatol, 2010;20(1):46–53.
3. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094–108.
4. Jones G, Ding C. Tocilizumab: a review of its safety and effi cacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2010;3:81–9.
5. Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, et al. Effi cacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol. 2011;21(2):122–33.
6. vanderVelde G, Pham B, Machado M, Ieraci L, Witteman W, Bombardier C, Krahn M. Cost-eff ectiveness of biologic response modifi ers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res. 2011;63(1):65–78.
7. Doan QV, Chiou CF, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infl iximab) in the management of rheumatoid arthritis. J Manag Care Pharm. 2006;12(7):555–69.
8. Soini EJ, Hallinen TA, Puolakka K, Vihervaara V, Kauppi MJ. Cost-eff ectiveness of adalimumab, etanercept, and tocilizumab as fi rst-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ. 2012;15(2):340–51.
9. Hirabayashi Y, Ishii T, Harigae H. Clinical effi cacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice. Rheumatol Int. 2010;30(8):1041–48.
10. Venkiteshwaran A. Tocilizumab. mAbs. 2009;1(5):432–8.
11. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Eff ect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008; 371(9617):987–97.
12. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, Kishimoto T. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): signifi cant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19(1):12–9.
13. Nishimoto N, Takagi N. Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the effi cacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study. Mod Rheumatol. 2010;20(6):539–47.
14. Hashimoto J, Garnero P, van der Heijde D, Miyasaka N, Yamamoto K, Kawai S, et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more eff ective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study Mod Rheumatol. 2011; 21(1):10-5.
15. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013; 381(9877): 1541-50.
16. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and effi cacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and effi cacy in a 5-year extension study. Ann Rheum Dis. 2009;68(10):1580-4.
17. European league against Rheumatism (EULAR) recommendations for management. Available from http://www.eular.org/index.cfm?framePage=/recommendations_management.cfm. Accessed on September 22, 2014.
18. Tanaka E, Hoshi D, Igarashi A, Inoue E, Shidara K, Sugimoto N, et al. Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA. Mod Rheumatol. 2013;23(4):742-51.
19. Diamantopoulos A, Finckh A, Huizinga T, Sungher DK, Sawyer L, Neto D, Dejonckheere F. Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Eff ectiveness Analysis in the UK. PharmacoEconomics. 2014;32(8):775-87.
20. Diamantopoulos A, Benucci M, Capri S, Berger W, Wintfeld N, Giuliani G, et al. Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy. J Med Econ. 2012;15(3):576-85.
21. Navarro Sarabia F, Blanco FJ, Alvaro Gracia JM, Garcia Meijide JA, Poveda JL, Rubio-Rodriguez D, Rubio-Terrés C. [Economic evaluation of rheumathoid arthritis monotherapy with tocilizumab and adalimumab]. RevEsp Salud Publica. 2013;87(4):343-50.
22. Kostic M, Jovanovic S, Tomovic M, Milenkovic MP, Jankovic SM. Cost-eff ectiveness analysis of tocilizumab in combination with methotrexate for rheumatoid arthritis: a Markov model based on data from Serbia, country in socioeconomic transition. Vojnosanit Pregl. 2014;71(2):144-8.
23. Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-eff ectiveness of infl iximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology. 2003;42(2):326-35.
24. Yamanaka H, Tohma S. Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice. Mod Rheumatol. 2006;16(2):75-6.
25. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322-38.
26. Hushaw LL, Sawaqed R, Sweis G, Reigle J, Gopal A, Brandt D, et al. Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag. 2010;6:143-52.
27. Said C, Coleiro B, Zarb Adami M, Azzopardi LM, Serracino Inglott A. Cost eff ectiveness of TNF-alpha Inhibitors in rheumatoid arthritis. Int J Inflam. 2013;2013:581409.
28. Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum. 1999;42(2):347-56.
29. Kobelt G, Jonsson L, Lindgren P, Young A, Eberhardt K. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2310-9.
30. Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K Modelling the eff ect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology. 2005;44(9): 1169-75.
31. Kobelt G, Lindgren P, Singh A, Klareskog L. Cost eff ectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis. 2005;64(8): 1174-9.
32. Tanno M, Nakamura I, Ito K, Tanaka H, Ohta H, Kobayashi M, et al. Modeling and cost-eff ectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis. Mod Rheumatol. 2006;16(2):77-84.
33. Price list of DPC/PDPS (Diagnosis Procedure Combination/Per-Diem Payment System). Available from [http://www.mhlw.go.jp/bunya/ iryouhoken/iryouhoken12/dl/setumei_15.pdf]. Accessed on July 2012.
34. Annual Report on the Labour Force Survey. Available from [http:// www.stat.go.jp/data/roudou/]. Accessed on July 2012.
35. Report of Basic Survey on Wage Structure. Available from [http://www.mhlw.go.jp/toukei/itiran/roudou/chingin/kouzou/detail/index. html]. Accessed on July 2012.
36. Jobanputra P. A clinician’s critique of rheumatoid arthritis health economic models. Rheumatology. 2011;50 Suppl 4:iv48-iv52.
37. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19(4):422–37.
38. A bridged Life Tables for Japan. Available from [http://www.mhlw.go.jp/english/database/db-hw/lifetb10/]. Accessed on July 2012.
39. Nakajima A, Inoue E, Tanaka E, Singh G, Sato E, Hoshi D, et al. Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol. 2010;39(5):360–7.
40. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516–23.
41. ter Wee MM, Lems WF, Usan H, Gulpen A, Boonen A. The eff ect of biological agents on work participation in rheumatoid arthritis patients: a systematic review. Ann Rheum Dis. 2012; 71(2): 161–71.
42. Welsing PM, Severens JL, Hartman M, van Riel PL, Laan RF. Modeling the 5-year cost eff ectiveness of treatment strategies including tumor necrosis factor-blocking agents and lefl unomide for treating rheumatoid arthritis in the Netherlands. Arthritis Rheum. 2004;51(6):964–73.
43. Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-eff ectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology. 2004;43(1):62–72.
44. Merkesdal S, Kirchhoff T, Wolka D, Ladinek G, Kielhorn A, Rubbert-Roth A. Cost-eff ectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure. Eur J Health Econ. 2010;11(1):95–104.
45. Kobelt G, Woronoff AS, Richard B, Peeters P, Sany J. Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study. Joint Bone Spine. 2008; 75(4): 408–15.
46. Tanaka E, Hoshi D, Igarashi A. Analysis of direct and indirect medical costs for the care of rheumatoid arthritis patients in a large cohort database, IORRA. Ann Rheum Dis. 2011;70:198.
47. Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Taniguchi A, et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum. 2003;49(6):784–8.
48. Yamanaka H. A Cohort Study of Clinical Care in Rheumatoid Arthritis: the IORRA study. Jpn Med Assoc J. 2009;52(1):54–6.
49. Tanaka E, Mannalithara A, Inoue E, Hara M, Tomatsu T, Kamatani N, et al. Effi cient management of rheumatoid arthritis signifi cantly reduces long-term functional disability. Ann Rheum Dis. 2008; 67(8): 1153–8.
50. Furuya T, Kotake S, Inoue E, Nanke Y, Yago T, Kobashigawa T, et al. Risk factors associated with incident clinical vertebral and nonvertebral fractures in Japanese women with rheumatoid arthritis: a prospective 54-month observational study. J Rheumatol. 2007;34(2):303–10.
51. Yamanaka H, Inoue E, Singh G, Tanaka E, Nakajima A, Taniguchi A, et al. Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol. 2007;17(4):283–9.
52. Nakajima A, Kamitsuji S, Saito A, Tanaka E, Nishimura K, Horikawa N, et al. Disability and patient’s appraisal of general health contribute to depressed mood in rheumatoid arthritis in a large clinical study in Japan. Mod Rheumatol. 2006;16(3):151–7.
53. Yamada T, Nakajima A, Inoue E, Tanaka E, Hara M, Tomatsu T, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis. 2006;65(12):1661–3.
54. Yamanaka H. A cohort study of clinical care in rheumatoid arthritis: the IORRA study. Jpn Med Assoc J. 2009;52:54–6.
55. Okuda Y. Review of tocilizumab in the treatment of rheumatoid arthritis. Biologics. 2008;2:75–82.
56. Jones G. The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis. Expert Rev Clin Immunol. 2010;6(2):189–95.
57. O’Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369(4):307–18.
58. Van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomized, non-blinded parallel-group Swefot trial. Lancet. 2012; 379(9827): 1712–20.
59. Eriksson JK, Karlsson JA, Bratt J, Petersson IF, van Vollenhoven RF, Ernestam S, et al. Cost-eff ectiveness of infl iximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomized controlled SWEFOT trial. Ann Rheum Dis. 2014;Apr 15.